MPXA-2000
Overview
Medipixel is a global healthcare company dedicated to improving the quality of human life by applying advanced AI technology to healthcare. Their primary focus is on revolutionizing diagnostic and treatment protocols within the cardiovascular field, with an expanding interest in neurovascular care. The flagship product, MPXA-2000, is an AI-based software medical device designed for the comprehensive analysis of cardiovascular angiography images.
MPXA-2000 seamlessly integrates into the cath lab workflow, providing real-time, automated quantitative analysis of coronary artery stenotic lesions. Utilizing cutting-edge deep learning and computer vision algorithms, it performs vessel segmentation and calculates precise dimensions, offering measurements comparable to those obtained through intravascular ultrasound (IVUS). This tool supports cardiologists and radiologists in making informed clinical decisions, evaluating interventions, and assessing drug therapies for adult patients with coronary artery disease (CAD).
Reviewed by Pouyan Golshani, MD — Interventional Radiologist
Key Features
- Automatic analysis of 2D angiography images
- AI algorithm for quantifying coronary artery stenotic lesions
- Provides measurements similar to intravascular ultrasound (IVUS)
- Real-time analysis of cardiovascular condition
- Supports clinicians in decision-making during PCI
- Vessel segmentation and lesion analysis
- Highly accurate quantitative analysis
- Compatible with DICOM standard X-ray angiographic images from Philips Medical Systems, Siemens Healthineers, GE Healthcare
Use Cases
- Supporting clinical decisions concerning coronary arteries
- Evaluating intervention or drug therapy for coronary artery conditions
- Quantitative analysis of cardiovascular images in cath labs
- Assisting in stent sizing during PCI procedures
What Physicians Need to Know
MPXA-2000 offers objective and reproducible quantitative coronary angiography (QCA) analysis, which can significantly reduce inter-operator variability in lesion assessment and stent sizing. Its real-time analytical capabilities provide crucial support for immediate clinical decisions during interventional procedures. Physicians can leverage this tool to enhance confidence in treatment planning and evaluate the efficacy of interventions or drug therapies for coronary artery conditions.
MPXA-2000 is designed for seamless integration into existing cath lab environments, accepting DICOM contrast images directly from cardiovascular imaging systems. Its AI-powered automation streamlines the image analysis workflow, providing rapid insights without requiring extensive operator intervention.
Details
| Category | Cardiology AI |
| Pricing | Unknown |
| Deployment | Stand-alone application; integrates seamlessly into cath lab workflow |
| Compliance | |
| BAA Available | Unknown AI-estimated |
| HIPAA Compliant | Unknown AI-estimated |
| FDA Status |
1 AI-estimated MPXA-2000 is a Class II medical device (Regulation Number: 21 CFR 892.2050, Product Code: QIH) that received U.S. FDA approval in March 2023. It is indicated for the viewing and quantification of X-ray angiographic images of coronary arteries in adult patients with coronary artery disease (CAD) to support clinical decisions. |
| Integrations | |
| EHR | Not specified |
| Specialties | Cardiology |
What the Web Says
The Medipixel MPXA-2000 is an AI-powered cardiovascular disease diagnosis assistance solution that has received FDA clearance. It is designed for real-time, automatic analysis of coronary angiographic images to detect and quantify stenosis in blood vessels. The system aims to provide invaluable data to medical professionals during cath lab procedures and has shown high concordance with manual quantitative coronary angiography (QCA).
Overall: PositiveStrengths
- FDA 510K clearance, a significant achievement for a South Korean AI medical device.
- Fully automated workstation for blood vessel segmentation and lesion analysis within 1-2 seconds, enabling real-time application.
- Automatic detection of blood vessels potentially affected by stenosis and quantification of the degree of stenosis.
- High concordance with manual QCA, offering prompt and accurate lesion estimation.
- Superior lesion detection capability compared to visual estimation, especially in images with multiple lesions.
- Seamless integration into clinical workflow and potential to bridge conventional angiography and imaging-guided PCI.
Limitations
- Some discomfort expressed by a physician regarding its comparison as a pre-PCI assessment tool with image-guided PCI, noting the value of intraprocedural and post-PCI feedback.
- Study limitations include using Minimum Lumen Area (MSA) as a surrogate marker rather than a clinical endpoint.
- Low complication rates at 6 months in a study limited definitive conclusions about procedural safety.
- Further studies are needed to validate its role in diagnosing and treating cardiovascular diseases when integrated into clinical practice.
- Data for some studies are not publicly available due to IRB restrictions, limiting independent verification.
Based on reviews from: Medipixel.io, TCTMD.com, PMC - NIH, accessdata.fda.gov
Last updated: 2026-07-18
Ratings & Reviews
No reviews yet. Be the first to review this tool!
Rate MPXA-2000
Press & Coverage
Videos
Product demos, reviews, and walkthroughs for MPXA-2000.
[BIOSTAR Interview] uc2ecud608uad00uc9c8ud658 uc2dcuc220uc2e4uc758 ub0b4ube44uac8cuc774uc158
ubcf4uac74uc0b0uc5c5ud601uc2e0ucc3duc5c5uc13cud130 KBIC
